Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9567753rdf:typepubmed:Citationlld:pubmed
pubmed-article:9567753lifeskim:mentionsumls-concept:C0030053lld:lifeskim
pubmed-article:9567753lifeskim:mentionsumls-concept:C0206146lld:lifeskim
pubmed-article:9567753pubmed:issue11lld:pubmed
pubmed-article:9567753pubmed:dateCreated1998-5-21lld:pubmed
pubmed-article:9567753pubmed:abstractTextEffect of oxyfedrine (OXF)(1 mg/kg) administered just before reperfusion (post-treatment) was investigated in a canine model of myocardial stunning. In the saline-treated animals, myocardial stunning was evidenced by fall in MAP, decrease in LV peak (+) dP/dt, rise in LVEDP and incomplete regeneration of myocardial ATP, after reperfusion. OXF was found to be effective in preventing the haemodynamic and metabolic changes associated with myocardial stunning.lld:pubmed
pubmed-article:9567753pubmed:languageenglld:pubmed
pubmed-article:9567753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9567753pubmed:citationSubsetIMlld:pubmed
pubmed-article:9567753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9567753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9567753pubmed:statusMEDLINElld:pubmed
pubmed-article:9567753pubmed:monthNovlld:pubmed
pubmed-article:9567753pubmed:issn0019-5189lld:pubmed
pubmed-article:9567753pubmed:authorpubmed-author:SethS DSDlld:pubmed
pubmed-article:9567753pubmed:authorpubmed-author:ManchandaS...lld:pubmed
pubmed-article:9567753pubmed:authorpubmed-author:MaulikS KSKlld:pubmed
pubmed-article:9567753pubmed:authorpubmed-author:MaulikMMlld:pubmed
pubmed-article:9567753pubmed:issnTypePrintlld:pubmed
pubmed-article:9567753pubmed:volume35lld:pubmed
pubmed-article:9567753pubmed:ownerNLMlld:pubmed
pubmed-article:9567753pubmed:authorsCompleteYlld:pubmed
pubmed-article:9567753pubmed:pagination1214-7lld:pubmed
pubmed-article:9567753pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:meshHeadingpubmed-meshheading:9567753-...lld:pubmed
pubmed-article:9567753pubmed:year1997lld:pubmed
pubmed-article:9567753pubmed:articleTitleOxyfedrine in myocardial stunning.lld:pubmed
pubmed-article:9567753pubmed:affiliationDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.lld:pubmed
pubmed-article:9567753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9567753pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed